Board of Directors
Jack Y. Zhang, Ph. D
Chief Executive Officer, President, Chief Scientific Officer, and Director
Jack Y. Zhang, Ph.D. has served as Amphastar Pharmaceutical’s Chief Executive Officer and as a member of the Board of Directors since its inception in 1996. He has also served as Amphastar’s Chief Scientific Officer since 2005 and as the President from 1996 until June 2013, and from April 2020 to present. Dr. Zhang has over 35 years of experience in chemistry, physics, management, and training including operations management of a chemical manufacturing facility with more than 2,000 employees to the start-up of an analytical laboratory serving defense cleanup. He is the co-founder of Applied Physics & Chemistry Laboratory (“APCL”), a full service, chemical analytical laboratory in Chino, California, where he held the position of President for 15 years. Dr. Zhang is named as the inventor on several U.S. and foreign patents and has authored numerous academic publications. He received a Ph.D. in Chemistry from the State University of New York at Stony Brook and was a Post Doctoral Research Associate at the California Institute of Technology.
Mary Z. Luo, Ph. D
Chief Operating Officer, Chief Scientist, and Chairman of the Board of Directors
Mary Z. Luo, Ph.D. has served as Chief Operating Officer for Amphastar Pharmaceuticals, Inc. and Chairman of the Board of Directors since its inception in 1996. She has also served as a Chief Scientist since 2005 and Corporate Secretary from 1996 through April 2004. As co-founder of both Amphastar Pharmaceuticals, Inc. and APCL, Dr. Luo has over 30 years of academic and practical experience in the field of chemistry. She provides scientific leadership through her research and activities in technology transfer, regulatory submission, intellectual property, clinical research, recruitment, and training. Dr. Luo is a professor emeritus of chemistry at California State Polytechnic University, Pomona and is named as the inventor on several U.S. and foreign patents. She received a Ph.D. in Chemistry from Princeton University and was a Post Doctoral Research Associate at the California Institute of Technology.
Richard Koo, C.P.A
Richard Koo, C.P.A. has served as a member of our Board of Directors since 2003. For over thirty years, Mr. Koo has been the managing partner of Koo, Chow and Company, Certified Public Accountants, and also serves as CEO and President of K.C. Group International Inc. and a Director of EverTrust Bank. Mr. Koo has extensive experience as a CPA in auditing and taxation and has worked with PricewaterhouseCoopers LLP in various public offering audit assignments. He has worked as a finance and taxation expert for the United Nations and has written numerous books and publications. Mr. Koo received a B.S. in Management from the National Taiwan University and an M.B.A. in Accounting from San Jose State University.
Richard Prins has served as a member of our Board of Directors since 2002. Mr. Prins began his career in 1983 as the Assistant to the Chairman of the leverage buyout company, Tuscarora Corp. He has 26 years of experience in all aspects of corporate finance and has participated directly in more than 150 transactions with both private and public companies across a number of industries in North America, Europe, and Asia. Mr. Prins was the Director of Investment Banking for Ferris, Baker Watts, Inc. (“FBW”), from 1996 until June of 2008 when FBW was acquired by Royal Bank of Canada. At FBW, he managed all of the firm's industry groups and product offerings including public offerings, mergers and acquisitions, private placements, restructurings, as well as other corporate advisory services activities. He was also responsible for executing a variety of financial and strategic transactions. Mr. Prins served as a consultant to Royal Bank of Canada Capital Markets through December 2008 to facilitate the post-acquisition transition. Prior to FBW, he was a Managing Director for eight years at Crestar Bank (now SunTrust Bank) in charge of Mergers and Acquisitions. Currently Mr. Prins is a private investor and involved in various charitable organizations. Also, he currently volunteers as acting head of US Operations for Advancing Native Missions and on the boards of directors of India Globalization Capital and Hilbert Technology. Mr. Prins received a B.A. in Liberal Arts from Colgate University and an M.B.A. from Oral Roberts University.
Howard Lee, Ph.D
Howard Lee, Ph.D. has served as a member of our Board of Directors since August 2007. He previously served as a member of the Board of one of our subsidiaries from 1998 to 2002 and Amphastar’s Board from 2002 to 2004. Dr. Lee is currently the partner at the CID Group, a prominent investment group in the greater China area. His previous commitment was the Chief Investment Officer at UniMed Venture Management Inc., a biotech venture capital firm. Prior to joining UniMed in July 2009, he was a Managing Director at Silver Biotech Management, Inc. for three years. Dr. Lee served as President and CEO of CDIB Biotech USA Investment Co. Ltd. from October 2000 to June 2006 and as Vice President of China Development Industrial Bank, a prominent investment bank in Taiwan, from October 1995 to June 2006. He carries broad industrial experience from conducting environmental engineering projects in diversified industries since 1993. He also serves as a director for the Development Center of Biotechnology in Taiwan. Dr. Lee earned his B.Sc. at Fu-Jen University (Taiwan), his M.Sc. and Ph.D. degrees in Chemistry from the University of Southern California in Los Angeles in 1990, and completed his postdoctoral research at Loker Hydrocarbon Research Institute of USC.
Michael A. Zasloff, M.D
Michael A. Zasloff, M.D., Ph.D. has served as a member of our Board of Directors since October 2005. Dr. Zasloff has been the Professor of Surgery and Pediatrics at the Georgetown University School of Medicine since January 2002, and was also the Dean of Research and Translational Science from January 2002 until July 2004. Between July 2004 and 2007, Dr. Zasloff served as Vice President and Senior Analyst (Life Sciences) at Ferris, Baker Watts, Inc. From 1992 to 2001 he served as Executive Vice President and Vice Chairman of Magainin Pharmaceuticals Inc., a publicly-held biopharmaceutical company which he founded, with research and development efforts in anti-angiogenesis, respiratory genomics and infectious disease. From 1988 until 1992, Dr. Zasloff served as the Charles E.H. Upham Professor, Department of Pediatrics and Genetics, University of Pennsylvania School of Medicine, and Chief, Division of Human Genetics and Molecular Biology at The Children's Hospital of Philadelphia. From 1982 until 1988, he was Chief, Human Genetics Branch, National Institutes of Child Health and Human Development, National Institutes of Health. Dr. Zasloff received a B.A. from Columbia College in Chemistry and holds an M.D., Ph.D. from the New York University School of Medicine. He is named the inventor on over 40 patents, has been widely published in scholarly journals, and has been the recipient of numerous awards.
Floyd F. Petersen, M.P.H
Floyd F. Petersen, M.P.H. has served as a member of our Board of Directors since August 2004. From 1986 to the present, Mr. Petersen has been an Assistant Professor of Biostatistics at Loma Linda University Schools of Public Health, Medicine, and Nursing. From 1990 to 2010, he served as Director of the Loma Linda University Health Research Consulting Group, which consults on health research study design and data analysis. He has personally consulted on over 700 health-related research projects. As a visiting professor, he has taught/consulted in health research in Chad, Romania, PR China, Thailand, Cambodia, PDR Lao, Kenya, Indonesia, Guam, and Russia. Mr. Petersen was a member of the Loma Linda, California City Council from 1990 to 2010 and served as the Mayor of Loma Linda from 1996 to 2006. Mr. Petersen is currently the vice-chair and a board member of Vtrans, a non-profit, quasi-governmental agency, which coordinates all public transportation for the elderly and handicapped in the Inland Empire of Southern California. He earned his M.P.H. in Public Health from Loma Linda University with concentrations in Biostatistics and Health Administration.
Diane G. Gerst, B.A
Diane G. Gerst served as the Company’s Executive Vice President of Quality Assurance and Regulatory Affairs from June 2015 until February 2018 and also served as the President of Amphastar Nanjing Pharmaceuticals Inc., one of the Company’s subsidiaries, from March 2014 until February 2018. From August 2013 to June 2015, Ms. Gerst served as the Company’s Corporate Senior Vice President of Quality Assurance. Ms. Gerst served as Corporate Vice President of Quality Assurance from August 2003 until her promotion to Senior Vice President in August 2013. Previously, she was the Company’s Vice President of Regulatory Affairs from June 2001 to July 2002. Prior to joining the Company, Ms. Gerst held various management level positions in regulatory and quality including eight years at Braun-McGaw and seven years at IMS. Ms. Gerst received a B.A. from the University of California, Berkeley.
David Maris, M.B.A
David Maris has been a private investor with Phalanx Investment Partners, LLC, an investment advisor, since January 2020. From December 2015 to December 2019, he was a managing director and equity research analyst at Wells Fargo Securities, LLC, an investment bank. From January 2013 to December 2015, Mr. Maris served as a managing director and equity research analyst at Bank of Montreal, an investment bank. He previously served as a healthcare industry equity analyst for several other investment banks, including Aros Securities (a Scandinavian bank), Bear Stearns and Company, Credit Suisse, Bank of America, and Credit Agricole-CLSA. Mr. Maris currently serves as a member of the American Finance Association and National Association of Corporate Directors. He holds a B.A. from the University of Delaware and an M.B.A. from Vanderbilt University’s Owen Graduate School of Management.